Pricing Log in Create free account

Oculis Holding AG (OCS) vs Ovid Therapeutics (OVID)

Oculis Holding AG and Ovid Therapeutics are both Biotechnology companies. Oculis Holding AG and Ovid Therapeutics are of similar size ($456.8M and $441.4M). Ovid Therapeutics grew revenue faster over the last twelve months: 1,333.4% against 65.8%. Ovid Therapeutics has the higher net margin (−439.1% vs −6,870.1%) and the lower return on invested capital (−35.1% vs 0.00%). Across the 16 metrics below, Ovid Therapeutics leads on 13 and Oculis Holding AG on 3.

Valuation

Metric OCS OVID Biotechnology median
P/E n/m n/m 8.50
P/S 303.32 54.05 9.71
P/B 1.61 2.02 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 108.92 40.55 9.21
Earnings yield (23.87%) (10.48%) (33.15%)
Free cash flow yield (18.51%) (12.94%) (25.50%)

Profitability

Metric OCS OVID Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (7,383.66%) (742.97%) 0.00%
Net margin (6,870.05%) (439.11%) 0.00%
Free cash flow margin (5,525.64%) (697.30%) 0.00%
Return on equity (44.87%) (25.97%) (56.36%)
Return on assets (37.69%) (22.30%) (48.04%)
Return on invested capital 0.00% (35.11%) 0.00%

Growth

Metric OCS OVID Biotechnology median
Revenue growth (TTM) 65.83% 1,333.39% 6.02%
EPS growth (last fiscal year) 5.39% 37.84% 30.26%
Revenue growth, 5-year CAGR — (10.48%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric OCS OVID Biotechnology median
Debt to equity 0.01 0.05 0.00
Current ratio 8.35 12.39 4.72
Net debt to EBITDA 2.60 1.37 0.96

Dividend

Metric OCS OVID Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric OCS OVID Biotechnology median
Market cap 456.82m 441.37m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack